Home | About the eMC | Help | Mobile
eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Advanced search
Get Medicines Compendium UK app here

sanofi-aventis
1 Onslow Street, Guildford, Surrey, GU1 4YS, UK
Telephone: +44 (0)1483 505 515
Fax: +44 (0)1483 535 432
Medical Information e-mail: uk-medicalinformation@sanofi-aventis.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?
Summary of Product Characteristics last updated on the eMC: 02/01/2009
SPC Dimetriose

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 02/01/2009 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Correction of spelling/typing errors
Date of revision of text on the SPC:   06-Feb-2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Sectino 4.3, addition of 'or to any of the excipients' to number one contraindication
Updated on 09/04/2008 and displayed until 02/01/2009
Reasons for adding or updating:
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 5.1 - Pharmacodynamic Properties
  • Change to section 5.3 - Preclinical Safety Data
Date of revision of text on the SPC:   02/2008
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
 
Change to section 4.4 Special Warnings and precautions for use
 
Addition of the following text: Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.
 
Change of thyroxine to levothyroxine
 
Section 5.1 Pharmacodynamic properties
 
Addition of the following text: Pharmacotherapeutic group: Antigonadotrophin, ATC code: G03XA02
 
Section 5.3 Preclinical safety data
 
Addition of the following text: There are no preclinical data of relevance which are additional to that already included in other sections of the SPC.

Additional formatting or rewording changes to sections 1; 2; 6.1; 6.2; 6.3 and 6.6 with no changes to meaning.
 
 
 
Updated on 13/08/2007 and displayed until 09/04/2008
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
Date of revision of text on the SPC:   11/2006
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company
Use of sanofi aventis trading style
Updated on 16/09/2005 and displayed until 13/08/2007
Reasons for adding or updating:
  • Improved Electronic Presentation
Updated on 01/01/0001 and displayed until 16/09/2005
Reasons for adding or updating:
  • No reasons supplied
Updated on 06/09/1999 and displayed until 01/01/0001
Reasons for adding or updating:
  • No reasons supplied

Active Ingredients/Generics

 
  gestrinone